Benign Prostatic Hyperplasia (BPH) – Study Guide for Medical Students

Definition

Benign Prostatic Hyperplasia (BPH) is a nonmalignant, proliferative enlargement of the prostate gland, characterized by hyperplasia of both stromal and epithelial elements predominantly within the periurethral (transition) zone. The increase in prostate volume leads to bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS), including both voiding and storage complaints. BPH is a histologic diagnosis, whereas benign prostatic enlargement (BPE) refers to the increase in size, and benign prostatic obstruction (BPO) describes the functional obstruction to urine flow.

Epidemiology

BPH is highly prevalent and strongly age-related. Histologic evidence of BPH is present in approximately 20% of men by age 40, 50%–60% by age 60, and up to 80%–90% by age 80. Clinically significant LUTS attributable to BPH increase with age and often impact quality of life. Many men have histologic BPH but remain asymptomatic, while others develop progressive LUTS, acute urinary retention, or complications such as recurrent infections and bladder stones.

Age: Major risk factor; prevalence rises sharply after age 50.
Ethnicity: Some data suggest higher rates and symptom burden in Black men, with variable findings across populations.
Family history: First-degree relatives with BPH are associated with increased risk and earlier onset.
Hormonal milieu: Normal testicular androgen production is required for BPH development; castrated males do not develop BPH.
Metabolic factors: Obesity, metabolic syndrome, and type 2 diabetes are associated with increased risk and more severe LUTS.

Pathophysiology

BPH arises from a complex interplay of hormonal, cellular, and stromal-epithelial interactions within the prostate, particularly in the transition zone around the urethra.

Hormonal mechanisms

Dihydrotestosterone (DHT): Testosterone is converted to DHT by 5α-reductase type 2 in prostatic stromal cells. DHT has higher affinity for androgen receptors and promotes growth of both stromal and epithelial cells. Lifelong androgen exposure, especially DHT, is central to gland enlargement.
Estrogen-androgen balance: With aging, serum testosterone levels decline while estradiol may be relatively preserved, altering the estrogen-to-androgen ratio. Estrogen may increase androgen receptor expression in prostate tissue and contribute to stromal proliferation.

Cellular and structural changes

Stromal-epithelial interactions: Growth factors (e.g., FGF, TGF-β) and cytokines from stromal cells modulate epithelial proliferation and apoptosis, favoring hyperplasia over time.
Transition zone predominance: Hyperplastic nodules develop mainly in the transition zone, circumferentially encasing the prostatic urethra. As nodules enlarge, they compress the urethral lumen and distort the bladder outlet.
Static vs dynamic components:
- Static component: The physical bulk of enlarged prostate tissue leading to mechanical obstruction.
- Dynamic component: Increased prostatic and bladder neck smooth muscle tone mediated by α₁-adrenergic receptors, causing functional narrowing of the urethra. This explains the rapid symptom relief seen with α₁-blockers.

Bladder response to obstruction

Detrusor hypertrophy in response to increased outlet resistance.
Detrusor overactivity leading to storage symptoms (urgency, frequency, nocturia).
With chronic obstruction, progressive detrusor decompensation, impaired contractility, increased postvoid residual (PVR), and risk of urinary retention and upper tract damage.

Clinical Presentation

Patients typically present with lower urinary tract symptoms (LUTS), which are conventionally divided into voiding (obstructive) and storage (irritative) symptoms. Symptom severity and bother are assessed using validated tools such as the International Prostate Symptom Score (IPSS).

Voiding (obstructive) symptoms

Weak or decreased urinary stream
Hesitancy and straining to initiate urination
Intermittency (start–stop stream)
Prolonged micturition time
Terminal dribbling
Incomplete emptying sensation

Storage (irritative) symptoms

Increased daytime frequency
Nocturia (waking at night to void)
Urgency, with or without urge incontinence
Urgency incontinence in some patients with detrusor overactivity

Complications and associated features

Acute urinary retention: Sudden inability to void, associated with suprapubic pain and palpable bladder.
Recurrent urinary tract infections: Due to incomplete emptying and stasis.
Bladder stones: Resulting from chronic stasis and infection.
Hematuria: From friable prostatic vessels or associated pathology.
Hydronephrosis and renal insufficiency: With chronic high-pressure retention or significant obstruction.

History and examination

History: Characterize LUTS (onset, duration, severity, pattern), nocturia, episodes of retention, hematuria, infections, medications (e.g., anticholinergics, sympathomimetics), and sexual function.
Digital rectal examination (DRE):
- BPH: Prostate typically enlarged, smooth, rubbery, and symmetric.
- Prostate cancer suspicion: Hard, irregular, nodular areas or asymmetry.
Assess lower abdomen for palpable distended bladder, and look for signs of renal impairment or neuropathy.

Diagnosis

BPH diagnosis is clinical, supported by symptom scores, physical examination, laboratory tests, and selected imaging or urodynamic studies. Key goals are to confirm LUTS related to BPH, exclude alternative pathology (e.g., malignancy, urethral stricture, neurogenic bladder), assess severity, and identify complications.

Initial evaluation

Symptom scoring:
- Use the International Prostate Symptom Score (IPSS) or AUA Symptom Index.
- IPSS classifies severity: 0–7 (mild), 8–19 (moderate), 20–35 (severe).
- Includes associated quality of life question.
Urinalysis:
- Screen for infection, hematuria, glycosuria.
- Identify alternative causes of LUTS such as UTI or bladder pathology.
Serum creatinine/eGFR (as indicated): Evaluate renal function in patients with possible obstruction or high-risk features.
Prostate-specific antigen (PSA):
- PSA may be measured if the result will influence management (e.g., cancer risk assessment, counseling regarding 5α-reductase inhibitor use).
- PSA can be elevated in BPH, but elevation is non-specific and requires appropriate interpretation.
Digital rectal exam (DRE): Assesses size, consistency, and nodularity.

Additional investigations (selective)

Postvoid residual (PVR) volume (ultrasound or bladder scan):
- Helps identify incomplete bladder emptying.
- Elevated PVR suggests more severe obstruction or detrusor underactivity.
Uroflowmetry:
- Noninvasive assessment of urinary flow rate and pattern.
- Reduced peak flow rate supports obstruction but is not specific.
Prostate imaging:
- Transrectal ultrasound (TRUS) or pelvic ultrasound can estimate prostate volume, evaluate median lobe, and assess bladder and upper tracts.
- Renal ultrasound may be used when upper tract damage is suspected.
Cystoscopy:
- Indicated when hematuria, suspected bladder pathology, urethral stricture, or prior to certain interventions.
Urodynamic studies:
- Reserved for complex cases: suspected neurogenic bladder, inconclusive evaluation, or prior failed surgery.

Management

Management aims to relieve LUTS, prevent complications, and improve quality of life. Options include watchful waiting (active surveillance), medical therapy, minimally invasive treatments, and surgery. The choice is based on symptom severity, prostate size, comorbidities, patient preference, and presence of complications.

1. Watchful waiting (Conservative management)

Appropriate for mild symptoms (IPSS 0–7) or minimally bothersome LUTS without complications.
Involves regular follow-up and education on lifestyle modifications.

Lifestyle and behavioral measures:

Reduce evening fluid intake to minimize nocturia.
Avoid or limit caffeine and alcohol (diuretic and bladder irritants).
Timed voiding or double voiding techniques to improve emptying.
Review and adjust medications that worsen LUTS (e.g., anticholinergics, decongestants with α-agonists).
Weight loss and optimizing control of diabetes and metabolic syndrome where applicable.

2. Medical therapy

Pharmacologic therapy is first-line for moderate to severe LUTS (IPSS ≥ 8) without absolute indication for surgery.

α₁-Adrenergic receptor blockers

Examples: Tamsulosin, alfuzosin, doxazosin, terazosin, silodosin.
Mechanism: Relax smooth muscle in the prostate and bladder neck by blocking α₁-adrenergic receptors, reducing dynamic obstruction and rapidly improving urinary flow.
Onset: Symptom improvement typically within days to weeks.
Adverse effects:
- Orthostatic hypotension, dizziness (more with non-selective agents).
- Asthenia, fatigue.
- Ejaculatory dysfunction (especially tamsulosin, silodosin).
- Intraoperative floppy iris syndrome in patients undergoing cataract surgery.

5α-Reductase inhibitors (5-ARIs)

Examples: Finasteride (type 2), dutasteride (type 1 and 2).
Mechanism: Inhibit conversion of testosterone to DHT, leading to reduction in prostate volume (especially in larger prostates) and lower risk of disease progression and acute urinary retention.
Indications:
- Moderate to severe LUTS with enlarged prostate (e.g., volume ≥ 30–40 mL or PSA suggestive of larger volume).
- Prevention of progression and reduction in need for surgery.
Onset: Symptomatic benefit develops over months (typically 3–6 months).
Adverse effects:
- Decreased libido, erectile dysfunction.
- Ejaculatory dysfunction.
- Gynecomastia or breast tenderness in some patients.
- Reduces PSA by ~50%; PSA values must be interpreted with this in mind (often PSA is doubled for cancer risk estimation after at least 6 months of therapy).

Combination therapy

Combining an α-blocker + 5-ARI is indicated in men with moderately to severely bothersome LUTS and clearly enlarged prostate at higher risk of progression.
Provides rapid symptom relief (α-blocker) and long-term reduction in prostate volume and risk of acute urinary retention or surgery (5-ARI).

Antimuscarinic agents and β₃-agonists

Antimuscarinics (e.g., oxybutynin, solifenacin, tolterodine) and β₃-agonists (e.g., mirabegron) may be used in men with predominant storage symptoms (urgency, frequency, urge incontinence) suggestive of overactive bladder.
Often used in combination with α-blockers in patients with both obstructive and overactive symptoms.
Care is required in men with high PVR or significant obstruction, as antimuscarinics can worsen retention; monitoring of PVR is recommended.

Phosphodiesterase-5 inhibitors (PDE5i)

Tadalafil (once daily) can improve LUTS and erectile dysfunction in men with both conditions.
Mechanism involves smooth muscle relaxation in the lower urinary tract and improved pelvic blood flow.
Useful for patients who prioritize sexual function and have concomitant erectile dysfunction.

3. Minimally invasive and surgical management

Interventional therapy is considered for patients with moderate to severe LUTS who fail or decline medical therapy, or those with complications of BPH (e.g., recurrent urinary retention, recurrent UTIs, bladder stones, significant hematuria, or renal dysfunction attributable to obstruction).

Transurethral resection of the prostate (TURP)

Gold standard surgical treatment for prostates in the small to moderate size range (typically < 80 mL, depending on local practice and technology).
Performed via endoscopic resection of obstructing prostatic tissue.
Benefits: Significant and durable improvement in flow rate and symptoms.
Complications:
- Retrograde ejaculation (common).
- Transient dysuria, hematuria.
- Urethral stricture, bladder neck contracture.
- Rare: TUR syndrome (with hypotonic irrigation fluids), incontinence.

Other surgical and minimally invasive options

Open or simple prostatectomy (including laparoscopic/robotic): For very large glands (often > 80–100 mL) where TURP is less feasible.
Holmium laser enucleation of the prostate (HoLEP) and other laser techniques: Enucleate or vaporize tissue with less bleeding and shorter catheterization; useful in large prostates.
Prostatic urethral lift (UroLift): Implants retract lateral lobes to open the urethral lumen; preserves ejaculatory function and suitable for selected patients without large median lobe.
Water vapor therapy (Rezūm): Convective water vapor ablation of prostate tissue, leading to reduction in obstruction over weeks.
Photoselective vaporization of the prostate (PVP) using GreenLight laser: Vaporizes obstructive tissue with lower bleeding risk.

4. Management of acute urinary retention

Immediate bladder decompression with urethral or suprapubic catheter.
Initiation or optimization of α-blocker therapy.
Trial without catheter (TWOC) after several days, often in conjunction with ongoing α-blocker.
Recurrent retention or failed TWOC typically warrants definitive surgical or minimally invasive intervention.

Key Clinical Pearls

BPH is histologic; LUTS are not specific. Always consider alternative and concurrent diagnoses (e.g., overactive bladder, prostate cancer, urethral stricture, neurologic disease).
Severity and bother drive treatment. Decision to treat and choice of therapy are guided by IPSS severity, impact on quality of life, prostate size, and patient preference, rather than prostate size alone.
α-blockers improve symptoms quickly by targeting the dynamic component of obstruction; 5-ARIs modify disease over months by shrinking prostate and reducing future risk of retention and surgery.
PSA is influenced by BPH and 5-ARIs. BPH can elevate PSA, and 5-ARIs reduce PSA by about 50%. When using PSA for cancer screening in patients on 5-ARIs, clinical interpretation must account for this reduction.
Storage symptoms may reflect detrusor overactivity. Addressing overactive bladder with antimuscarinics or β₃-agonists (often combined with an α-blocker) is important when urgency and frequency predominate, but PVR should be monitored.
Complications signal the need for intervention. Recurrent urinary retention, recurrent UTIs, bladder stones, gross hematuria, or renal impairment in the context of BPH typically require procedural or surgical management.
DRE and PSA remain essential in evaluating men with LUTS to differentiate BPH from prostate malignancy and to guide workup and follow-up.
Bladder changes may be irreversible. Chronic obstruction can lead to detrusor decompensation; early identification and treatment of significant obstruction can help preserve bladder and renal function.

Summary for Exams

BPH is a benign proliferation of stromal and epithelial tissue in the transition zone, driven largely by DHT and aging-related hormonal changes.
Presents with LUTS (voiding and storage), with IPSS used to quantify severity.
Diagnosis is clinical, supported by DRE, urinalysis, PSA, and selected imaging or functional tests.
First-line management ranges from watchful waiting for mild symptoms to α-blockers and 5-ARIs for moderate to severe LUTS.
TURP remains the standard operative intervention, with multiple minimally invasive alternatives available.